TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: severe respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: ventilatory frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Endothelium-dependent vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Hcy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high loudness symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: painful throat symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum phonation time (MPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic ultrasonography score in the gastric cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic ultrasonography score on the gastric wall surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to lung toxicity
Endpoint domain: Mortality/survival
Primary endpoint: Net oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net perceived exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of glottis exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relieving depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improving psychological state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postoperative oxygenation mean PaO2/FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PGD grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional elasticity of tissue surrounding atherosclerotic plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Bone Mineral Density (BMD) at spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bone Mineral Density (BMD) at hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of weeks with depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of (hypo)manic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of emergence reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Serum total CO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid function (free T3, total T3, free T4, TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in HDRS-21 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe bilateral loss of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: extensive choroidal neovascularization with major subretinal hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CAG repeat length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average breathlessness/24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nurses' inquiries about CAM therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nurses' referral to CAM therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sexual dysfunction (SD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Power of single sweeps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phase-locking properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AQLQ overall score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Asthma related clinic visits
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency department visits
Endpoint domain: Adverse events/effects
Primary endpoint: Sway speed with eyes open
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway speed with eyes closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H1/stalk IgG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in post‐bronchodilator FEV(1) % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Local disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in tooth color (ΔE*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCC variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average hospitalization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: aggregate WOMAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NDI recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: human fecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of spontaneous sinus rhythm after myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of defibrillation for ventricular reperfusion arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Polymorphonuclear leukocyte TNF‐alpha and IL‐1 beta receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Superoxide anion production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Candicidal activity of polymorphonuclear leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body Fat Percentage (BF%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with X-ray lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of new patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metaphyseal repair rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean vicriviroc C(max) and AUC ratio estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of parotitis
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of lymphadenopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Nighttime/daytime asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FEV1 improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total social cost
Endpoint domain: Resource use
Primary endpoint: Fear of Falling (FES scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freezing of Gait (FOG scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of SPADI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inhibition of CYP3A4/5 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates greater than 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects on the gastrointestinal tract
Endpoint domain: Adverse events/effects
Primary endpoint: Elevations of liver enzyme levels
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients newly prescribed oral anticoagulants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for tablet PC vs paper form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: occlusion of dentinal tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in lumbar BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in serum OC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in urinary DPD-Cr levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative time in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Convalescence time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in IHC in the anterior frontal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilization of delta band in the posterior frontal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient management (SWAT-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-technical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall health profile score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nutrition
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in blood fat index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Training adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: persistent disabling back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Life-years gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Grade 2 or greater late side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate (IOP < 18 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean IOP at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: CABG and PTCA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median decline in fasting TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in high sensitivity C reactive protein (hsCRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in arachidonic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interest in disclosure of AD research results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hair count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting practices
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parents' perception of child's behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum TT3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Verbal comprehension IQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Language comprehension during the scanning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of CT and relatedness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: alanine aminotransferase (ALT) elevation
Endpoint domain: Adverse events/effects
Primary endpoint: Prepulse Facilitation (PPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Curiosity to try an e‐cigarette
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood of e‐cigarette trial at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lip or mucosal trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Bowel obstruction complications
Endpoint domain: Adverse events/effects
Primary endpoint: urinary ratio of alphaCTX to betaCTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral glucose sensitivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: meal-derived insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulating fibroblast-growth factor 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentration biomarkers of vitamins and carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Daily Energy Expenditure (TDEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-Exercise Activity Thermogenesis (NEEx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-Exercise Physical Activity (NEPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean sedation grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean onset of sedative effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonged sedation
Endpoint domain: Adverse events/effects
Primary endpoint: mean maxillary widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliable genomic DNA test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum IL-4, IL-12 and IFN-γ concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C-reactive protein (CRP) elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of abortion within day 1
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of headache 3 hours after induction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of neural-tube defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Foundational status of neurosurgical studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in gamma brainwaves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self-assessed happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-assessed stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: empathy index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment-related adverse-event frequency and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Pseudomonas aeruginosa pneumonia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Mean astigmatism correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in refraction spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of organ failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in physical violence victimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in psychological perpetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant acceptance of the research protocol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall symptoms (pain, fatigue, and depression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walk time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin A deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Non-participation in lung screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Defibrillation threshold (DFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lequesneos index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anginal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intake of nitroglycerin tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in pruritus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective rash score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of prealbumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of retinol-binding protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physician-derived score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of alkaline phosphatase (AKP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: serum concentration of aspartate aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: serum concentration of gamma glutamyltransferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in monthly convulsive seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Longest seizure-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: POMS Tension-Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: POMS Confusion-Bewilderment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anger-Hostility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: JA initiation during interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of JE with mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of grades 2-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of suspected abacavir hypersensitivity reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of right-to-left shunts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thyrotropin (TSH) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total triiodothyronine (T3) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroxine (T4) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Effectiveness of diazepam AI treatments (no subsequent seizure or rescue)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of subsequent seizures experienced by subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esophageal acid reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean interocular disparity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes